Trials / Completed
CompletedNCT04829552
Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units
Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units: A Multicenter Retrospective Cohort Study in the Beaumont Healthcare System
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 704 (actual)
- Sponsor
- Corewell Health East · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, retrospective, study to determine if therapeutic dose anticoagulation (High dose group) improves inpatient mortality in severely ill patients with COVID-19 compared to prophylactic dose anticoagulation (Low dose group). The study involved 704 individuals who were admitted to Beaumont Health System (BHS) from March 10th to April 15th, 2020.
Conditions
Timeline
- Start date
- 2020-03-10
- Primary completion
- 2020-04-15
- Completion
- 2020-04-15
- First posted
- 2021-04-02
- Last updated
- 2021-04-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04829552. Inclusion in this directory is not an endorsement.